CEO: James J. Noble

Sector: Healthcare
Industry:Biotechnology

Exchange: Nasdaq Global Select

Country: USA

Description: Adaptimmune Therapeutics PLC along with its subsidiaries is a clinical-stage biopharmaceutical company. It is engaged in novel cancer immunotherapy products based on its T-cell receptor platform.


Key numbers

Market Capitalization:76245092
Shares Outstanding: 105165644.333333
Float: 87678806.15923071
Next Earning Date:2020-03-11
TTm EPS: -0.9433
TTm Dividend Rate:
200 days moving average:3.0536
50 days moving average: 1.2346
One day percent Change: -0.85



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,